Frontotemporal dementia (FTD) is diagnosed through a combination of behavioral assessment, cognitive testing, brain imaging, and sometimes genetic testing or fluid biomarkers. There is no single test that confirms it. The process typically takes years, with the average time from first symptoms to a correct diagnosis sitting around 4.4 years. That delay happens partly because FTD symptoms often look like psychiatric conditions, and partly because the disease is less well-known than Alzheimer’s.
Why FTD Is So Often Missed Early On
FTD tends to strike younger than Alzheimer’s, often between ages 45 and 65, and its earliest symptoms are behavioral rather than memory-related. That combination leads to frequent misdiagnosis. In one study of patients who eventually received a confirmed FTD diagnosis, 71.4% were initially misdiagnosed with a psychiatric condition during their first hospital visit. Women were most often told they had depression or bipolar disorder, while men were commonly diagnosed with anxiety or psychotic disorders.
On average, patients waited about 2.1 years before even seeking medical attention, then spent another 2.3 years in the psychiatric system before receiving the correct diagnosis. This is a defining challenge of FTD: the symptoms that matter most, like personality changes, loss of empathy, compulsive behaviors, and apathy, don’t look like dementia to most people, including many clinicians who encounter them first.
The Behavioral Assessment
The foundation of an FTD diagnosis is a careful evaluation of behavioral and personality changes, usually gathered from both the patient and someone who knows them well. Under the international consensus criteria, a person must show progressive deterioration in behavior or cognition, and at least three of six core features need to be present for a diagnosis of “possible” behavioral variant FTD:
- Behavioral disinhibition: acting impulsively, making inappropriate comments, or losing social awareness
- Apathy or inertia: loss of motivation or interest in activities that previously mattered
- Loss of empathy: reduced emotional response to others, appearing indifferent to loved ones’ feelings
- Repetitive or compulsive behavior: rigid routines, hoarding, repeating phrases or movements
- Changes in eating habits: binge eating, strong cravings for sweets, or putting inedible objects in the mouth
- Executive dysfunction with preserved memory: difficulty with planning and problem-solving, but relatively intact recall of recent events
That last point is critical for distinguishing FTD from Alzheimer’s. In Alzheimer’s, memory loss is typically the first and most prominent symptom. In behavioral variant FTD, memory often stays relatively intact in the early stages while behavior and personality deteriorate. Disinhibition, in particular, is the single feature shown to reliably distinguish the two conditions over time, even though other executive functions decline at similar rates in both.
Diagnosing the Language Variants
FTD isn’t just one disease. It also includes primary progressive aphasia (PPA), a group of conditions where language breaks down as the dominant early symptom. Clinicians classify PPA into three subtypes, each with a distinct pattern.
In the nonfluent variant, speech becomes slow and effortful. Sentences are short and grammatically broken, with words dropped or rearranged. Patients often know what they want to say but struggle to physically produce the sounds correctly, making distortions, deletions, and substitutions they’re usually aware of.
The semantic variant looks different. Speech flows smoothly and stays grammatically intact, but the meaning drains out of words. Patients lose the ability to understand individual words, especially uncommon ones. This reflects a deeper breakdown in the brain’s concept system: they may also fail to recognize familiar objects or faces regardless of whether they see, hear, or touch them. A telltale sign is difficulty reading or spelling words that don’t follow standard pronunciation rules.
In the logopenic variant, the hallmark is frequent pausing. Patients search for words constantly, producing slow speech with long gaps, but without the grammatical errors seen in the nonfluent type. They also struggle to repeat sentences back, especially long ones. Unlike the semantic variant, they can still understand individual words. This subtype is actually more closely linked to Alzheimer’s pathology than to FTD pathology, but it’s diagnosed within the same framework.
Cognitive and Neuropsychological Testing
Standardized cognitive tests play an important supporting role, though they have real limitations in FTD. Classic tests used in the evaluation include verbal fluency tasks (generating as many words as possible starting with a specific letter), card-sorting tests that measure mental flexibility, and trail-making tests that require alternating between numbers and letters under time pressure. These assess executive function: the ability to plan, shift strategies, and organize information.
The problem is that many of the most disruptive FTD symptoms, like loss of empathy, rigid behavior, and social inappropriateness, don’t show up on these traditional tests. More specialized assessments can help. The “hotel task,” for instance, asks patients to manage five different hotel-related activities within 15 minutes while also remembering to perform a timed task. It measures real-world multitasking and time management, skills that deteriorate early in FTD. Gambling tasks that test decision-making under risk also reveal patterns specific to frontal lobe damage, where patients consistently chase large immediate rewards despite repeated losses.
No single cognitive test confirms FTD. The pattern matters more than any individual score: executive and social cognition deficits with relatively preserved memory and spatial skills point toward FTD rather than Alzheimer’s.
Brain Imaging
Imaging moves a diagnosis from “possible” to “probable” under the consensus criteria. Two types of scans are most useful.
Structural scans (MRI or CT) look for shrinkage in the frontal lobes and the front portions of the temporal lobes. This pattern of atrophy in the front of the brain, with the back of the brain looking relatively normal, is characteristic of FTD. Notably, the hippocampus (a memory structure) can also shrink in FTD, which sometimes causes confusion with Alzheimer’s. The key difference is that in Alzheimer’s, the surrounding medial temporal lobe structures also atrophy, while in FTD those areas are typically spared. That distinction helps radiologists tell the two apart.
Functional scans, particularly FDG-PET, measure how actively different brain regions are using glucose. In FTD, the frontal lobes and front portions of the temporal lobes show reduced metabolic activity. Reduced activity in the anterior cingulate region is especially telling, with a specificity above 93% for FTD in one analysis. Alzheimer’s, by contrast, shows reduced metabolism in the back of the brain, particularly in the parietal and posterior temporal regions and the posterior cingulate. When the scan shows a clear front-of-brain pattern, it provides strong evidence for FTD over Alzheimer’s.
Blood and Spinal Fluid Biomarkers
Biomarker testing is increasingly part of the diagnostic workup, though it serves more to rule out other conditions than to confirm FTD directly. One marker gaining attention is neurofilament light chain (NfL), a protein released when nerve cells are damaged. People with FTD have NfL levels roughly three times higher than healthy individuals in spinal fluid, and about 2.5 times higher in blood. These levels tend to be even higher than what’s seen in Alzheimer’s, likely because of the extensive damage FTD causes in frontal, temporal, and subcortical brain areas.
The catch is that NfL rises in many neurological conditions, not just FTD. When researchers compared FTD patients to people with conditions that mimic FTD (the comparison that matters most in a real clinical setting), NfL’s ability to distinguish between them was only modest. It’s most useful as a general signal of neurodegeneration, not a specific FTD fingerprint. Spinal fluid tests for Alzheimer’s-related proteins (amyloid and tau) are often more valuable in the diagnostic process, because a negative Alzheimer’s biomarker result in someone with dementia symptoms shifts the likelihood toward FTD or another non-Alzheimer’s cause.
Genetic Testing
FTD has a stronger genetic component than most other dementias. About 10 to 20% of cases are clearly familial, and three genes account for the majority of inherited cases. The most common is the C9orf72 repeat expansion, found in roughly 13.5% of familial FTD cases and about 2.6% of cases with no known family history. Mutations in the GRN gene (progranulin) account for another 2 to 3% of familial cases. The MAPT gene, which produces tau protein, is the third major culprit, though its prevalence varies by population.
Genetic testing is typically offered when someone has a strong family history of dementia, ALS, or both (FTD and ALS share genetic overlap, particularly through C9orf72). A confirmed genetic mutation represents the only way to reach a “definite” FTD diagnosis during a patient’s lifetime, short of a brain biopsy. For families with a known mutation, presymptomatic testing is available, though it raises complex personal decisions since no preventive treatment currently exists.
How the Diagnosis Comes Together
In practice, FTD diagnosis is layered. It starts with recognizing a pattern of behavioral or language changes that doesn’t fit typical Alzheimer’s or a psychiatric condition. Cognitive testing confirms the expected profile of deficits. Imaging provides structural or metabolic evidence. Biomarkers help rule out Alzheimer’s. Genetic testing, when appropriate, can provide definitive confirmation.
The consensus criteria formalize this into tiers. “Possible” FTD requires the right clinical picture. “Probable” FTD adds supporting imaging findings and clear functional decline reported by someone close to the patient. “Definite” FTD requires either a pathogenic gene mutation or, after death, examination of brain tissue confirming the characteristic protein deposits. Most living patients receive a “probable” diagnosis, which in expert hands is accurate the large majority of the time but still carries some uncertainty. Getting to a specialized memory clinic or a neurologist experienced with FTD significantly reduces the chance of misdiagnosis and shortens the years-long delays that remain common.